A pilot study of vagus nerve stimulation (VNS) for treatment-resistant anxiety disorders

Brain Stimulation

Volumn 1, Issue 2, 2008, Pages 112-121

  George, Mark S ^a   Ward Jr , Herbert E ^b   Ninan, Philip T ^c   Pollack, Mark ^d   Nahas, Ziad ^a   Anderson, Berry ^a   Kose, Samet ^a   Howland, Robert H ^e   Goodman, Wayne K ^b   Ballenger, James C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

anxiety disorder; clinical trial; efficacy; obsessive compulsive disorder; panic disorder; posttraumatic stress disorder; side effects; vagus nerve stimulation (VNS)

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BUSPIRONE; CENTRAL STIMULANT AGENT; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; LORAZEPAM; METHYLPHENIDATE; MIRTAZAPINE; MOOD STABILIZER; NALTREXONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIOTIXENE; UNINDEXED DRUG; ZALEPLON; ZIPRASIDONE; ZOLPIDEM;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITIVE THERAPY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HAMILTON ANXIETY SCALE; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT; PANIC; PATIENT SAFETY; PILOT STUDY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; VAGUS NERVE STIMULATION; ANATOMY AND HISTOLOGY; ANXIETY DISORDERS; BRAIN; CLINICAL TRIAL (TOPIC); DEPRESSIVE DISORDER, MAJOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANXIETY DISORDERS; BRAIN; CLINICAL TRIALS AS TOPIC; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; STRESS DISORDERS, POST-TRAUMATIC; TREATMENT FAILURE; TREATMENT OUTCOME; VAGUS NERVE STIMULATION; YOUNG ADULT;

EID: 43749118026     PISSN: 1935861X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brs.2008.02.001     Document Type: Article

References (43)

1. D.V. Sheehan K.H. Sheehan Current approaches to the pharmacologic treatment of anxiety disorders Psychopharmacol Bull 40 1 2007 98 109
2. R.C. Kessler The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective J Clin Psychiatry 68 Suppl 2 2007 10 19
3. B.O. Olatunji J.M. Cisler D.F. Tolin Quality of life in the anxiety disorders: a meta-analytic review Clin Psychol Rev 27 5 2007 572 581
4. B.H. Friedman An autonomic flexibility-neurovisceral integration model of anxiety and cardiac vagal tone Biol Psychol 74 2 2007 185 199
5. M.S. George H.A. Sackeim A.J. Rush Vagus nerve stimulation: a new tool for brain research and therapy Biol Psychiatry 47 4 2000 287 295
6. M.S. George Z. Nahas D.E. Bohning Vagus nerve stimulation: a research update Neurology 54 Suppl 4 2002 S56 S61
7. T.R. Henry Therapeutic mechanisms of vagus nerve stimulation Neurology 59 Suppl 4 2002 S15 S20
8. S.E. Krahl K.B. Clark D.C. Smith R.A. Browning Locus coeruleus lesions suppress the seizure attenuating effects of vagus nerve stimulation Epilepsia 39 1998 709 714
9. M.A. Smith S. Makino M. Altemus Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in the locus coeruleus Proc Natl Acad Sci U S A 92 19 1995 8788 8792
10. H. Hirata G. Aston-Jones A novel long-latency response of locus coeruleus neurons to noxious stimuli: mediation by peripheral C-fibers J Neurophysiol 71 5 1994 1752 1761
11. S. Kapur M.C. Austin M.D. Underwood V. Arango J.J. Mann Electroconvulsive shock increases tyrosine hydroxylase and neuropeptide Y gene expression in the locus coeruleus Brain Res Mol Brain Res 18 1-2 1993 121 126
12. S. Nakamura Axonal sprouting of noradrenergic locus coeruleus neurons following repeated stress and antidepressant treatment Prog Brain Res 88 1991 587 598
13. P.L. Delgado W.K. Goodman L.H. Price G.R. Heninger D.S. Charney Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder Br J Psychiatry 157 1990 762 765
14. W.K. Goodman L.H. Price S.A. Rasmussen G.R. Heninger D.S. Charney Fluvoxamine as an antiobsessional agent Psychopharmacol Bull 25 1989 31 35
15. E. Ben-Menachem A. Hamberger T. Hedner Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures Epilepsy Res 20 1995 221 227
16. J.H. Chae Z. Nahas M. Lomarev A review of functional neuroimaging studies of vagus nerve stimulation (VNS) J Psychiatr Res 37 6 2003 443 455
17. D.E. Bohning M.P. Lomarev S. Denslow Z. Nahas A. Shastri M.S. George Feasibility of vagus nerve stimulation-synchronized blood oxygenation level-dependent functional MRI Invest Radiol 36 8 2001 470 479
18. M. Lomarev S. Denslow Z. Nahas J.H. Chae M.S. George D.E. Bohning Vagus nerve stimulation (VNS) synchronized BOLD fMRI suggests that VNS in depressed adults has frequency/dose dependent effects J Psychiatr Res 36 4 2002 219 227
19. Q. Mu D.E. Bohning Z. Nahas Acute vagus nerve stimulation using different pulse widths produces varying brain effects Biol Psychiatry 55 8 2004 816 825
20. Z. Nahas C. Teneback J.H. Chae Serial vagus nerve stimulation functional MRI (VNS/fMRI) in Treatment resistant depression Neuropsychopharmacol 32 2 2007 1 12
21. S.E. Krahl S.S. Senanayake A. Handforth Seizure suppression by systemic epinephrine is mediated by the vagus nerve Epilepsy Res 38 2000 171 175
22. S.E. Krahl S.S. Senanayake A. Handforth Destruction of peripheral C-fibers does not alter subsequent vagus nerve stimulation-induced seizure suppression Epilepsia 42 2001 586 589
23. A.J. Rush M.S. George H.A. Sackeim Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study Biol Psychiatry 47 4 2000 276 286
24. H.A. Sackeim J.G. Keilp A.J. Rush The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression Neuropsychiatry Neuropsychol Behav Neurol 14 1 2001 53 62
25. H.A. Sackeim A.J. Rush M.S. George Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome Neuropsychopharmacol 25 5 2001 713 728
26. Z. Nahas L.B. Marangell M.M. Husain Two-year outcome of vagus nerve stimulation (VNS) therapy for major depressive episodes J Clin Psychiatry 66 2005 1097 1104
27. M.S. George A.J. Rush L.B. Marangell A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression Biol Psychiatry 58 5 2005 364 373
28. A.J. Rush L.B. Marangell H.A. Sackeim Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial Biol Psychiatry 58 5 2005 347 354
29. A.J. Rush H.A. Sackeim L.B. Marangell Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study Biol Psychiatry 58 5 2005 355 363
30. R.M. Post J.C. Ballenger T.W. Uhde W.E.J. Bunney Efficacy of carbamazepine in manic-depressive illness: implications for underlying mechanisms R.M. Post J.C. Ballenger Neurobiology of Mood Disorders 1984 Williams and Wilkins Baltimore 777 816
31. R.M. Post T.W. Uhde J.C. Ballenger K.M. Squillace Prophylactic efficacy of carbamazepine in manic-depressive illness Am J Psychiatry 140 1983 1602 1604
32. J.C. Ballenger R.M. Post Anticonvulsants in psychiatric disease: when are they effective? Drug Therapy 15 1985 144 156
33. M. Mula S. Pini G.B. Cassano The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence J Clin Psychopharmacol 27 3 2007 263 272
34. E. Ben-Menachem R. Manon-Espaillat R. Ristanovic Vagus nerve stimulation for treatment of partial seizures: 1, a controlled study of effect on seizures Epilepsia 35 1994 616 626
35. R. George M. Salinsky R. Kuzniecky Vagus nerve stimulation for treatment of partial seizures: 2, long-term follow-up on first 67 patients exiting a controlled study Epilepsia 35 1994 637 643
36. A.J. Rush M.S. George H.A. Sackeim Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study Biol Psychiatry 47 2000 276 286
37. H.A. Sackeim A.J. Rush M.S. George Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome Neuropsychopharmacol 25 5 2001 713 728
38. M.H. Trivedi A.J. Rush H.M. Ibrahim The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation Psychol Med 34 1 2004 73 82
39. R.C. Young J.T. Biggs V.E. Ziegler D.A. Meyer A rating scale for mania: reliability, validity and sensitivity Br J Psychiatry 133 1978 429 435
40. J.E. Ware C.D. Sherbourne The MOS 36-item short-form health survey (SF-36): I, conceptual framework and item selection Med Care 30 1992 473 483
41. B.D. Greenberg L.H. Price S.L. Rauch Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues Neurosurg Clin N Am 14 2 2003 199 212
42. B.D. Greenberg D.A. Malone G.M. Friehs Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder [erratum appears in Neuropsychopharmacol 2006 Nov;31(11):2394] Neuropsychopharmacol 31 11 2006 2384 2393
43. W. James What is an emotion? Mind 9 1884 188 205